Cover Image
市場調查報告書

組織胺H4受體:開發中產品分析

Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 359402
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
組織胺H4受體:開發中產品分析 Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2016
出版日期: 2016年09月30日 內容資訊: 英文 61 Pages
簡介

本報告提供組織胺H4受體的開發情形相關調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息與新聞稿等資訊。

簡介

  • 調查範圍

組織胺H4受體概要

治療藥的開發

組織胺H4受體:開發中的產品 - 各開發階段

組織胺H4受體:開發中的產品 - 各治療範圍

組織胺H4受體開發中的產品 - 各適應症

組織胺H4受體:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

組織胺H4受體:企業開發中的產品

組織胺H4受體:治療藥的評估

  • 單劑產品
  • 各產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

組織胺H4受體的治療藥開發企業

  • Chrysalis Pharma SAS
  • Griffin Discoveries BV
  • Johnson & Johnson
  • OSE Pharma SA
  • Palau Pharma, S.A.
  • Sensorion S.A.
  • Ziarco Pharma Ltd

組織胺H4受體:藥物簡介

組織胺H4受體:暫停中的計劃

組織胺H4受體:開發中止的產品

組織胺H4受體:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0571TDB

Summary

Global Markets Direct's, 'Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Review, H2 2016', provides in depth analysis on Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted pipeline therapeutics.

The report provides comprehensive information on the Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4)
  • The report reviews Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) Overview
  • Therapeutics Development
    • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Products under Development by Stage of Development
    • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Products under Development by Therapy Area
    • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Products under Development by Indication
  • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Products under Development by Companies
  • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Companies Involved in Therapeutics Development
    • Chrysalis Pharma SAS
    • Griffin Discoveries BV
    • Johnson & Johnson
    • OSE Immunotherapeutics
    • Palau Pharma, S.A.
    • Sensorion S.A.
    • Ziarco Pharma Ltd
  • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Drug Profiles
    • GD-134 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GD-136 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GD-48 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-28307474 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-28610244 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JNJ-40279486 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SENS-218 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize Histamine H4 Receptor for Cystic Fibrosis and Idiopathic Pulmonary Fibrosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Histamine H1 and H4 Receptor for Ophthalmology and Asthma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Histamine H4 Receptor for Vestibular Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • toreforant tartrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tritoqualine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • UR-63325 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZPL-389 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Dormant Projects
  • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Discontinued Products
  • Histamine H4 Receptor (AXOR35 or G Protein Coupled Receptor 105 or GPRv53 or Pfi-013 or SP9144 or GPCR105 or HRH4) - Featured News & Press Releases
    • Sep 19, 2016: Sensorion Presents Results of 2 Preclinical Trials at the 2016 IEB congress
    • Sep 07, 2016: Sensorion Announces Positive Results From SENS-218 Phase 1 Clinical Trial Undertaken in the UK
    • Sep 01, 2016: Sensorion Obtains FDA Approval to Initiate a Clinical Study of SENS-111 in Acute Severe Vertigo
    • Jun 13, 2016: Ziarco reports positive Phase 2a study results with ZPL-389 in moderate to severe atopic dermatitis patients
    • May 16, 2016: Ziarco Pharma Announces Positive Top Line Results from Phase 2a Study in Moderate to Severe Atopic Dermatitis with its Oral Lead Compound ZPL-389
    • May 12, 2016: Sensorion to Present Data from Phase 1b Clinical Trial of SENS-111 at AAO-HNSF Annual Meeting
    • Feb 22, 2016: Sensorion Presents SENS-218 Data at Association for Research in Otolaryngology Meeting
    • Feb 02, 2016: Phase 2a Psoriasis Study Initiated with Ziarco Lead Compound ZPL-389
    • Jan 06, 2016: Sensorion Receives Approval from the UK Drug Agency to Initiate Clinical Trial of SENS-218
    • Jun 10, 2015: Ziarco Initiates Phase 2a Clinical Trial of ZPL-389 in Atopic Dermatitis
    • Apr 23, 2015: Sensorion successfully completes the first part of the clinical trial on SENS-111, which aims to treat severe bouts of vertigo
    • Jun 18, 2014: Ziarco Secures £1.7M Grant from UK's Technology Strategy Board to Support Phase 2a of ZPL-389 in Atopic Dermatitis
    • Jun 08, 2010: Palau Pharma Reports Positive First-In-Man Phase I Clinical Trial Results For Its Histamine H4 Receptor Antagonist UR-63325
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by Chrysalis Pharma SAS, H2 2016
  • Pipeline by Griffin Discoveries BV, H2 2016
  • Pipeline by Johnson & Johnson, H2 2016
  • Pipeline by OSE Immunotherapeutics, H2 2016
  • Pipeline by Palau Pharma, S.A., H2 2016
  • Pipeline by Sensorion S.A., H2 2016
  • Pipeline by Ziarco Pharma Ltd, H2 2016
  • Dormant Projects, H2 2016
  • Dormant Projects (Contd..1), H2 2016
  • Dormant Projects (Contd..2), H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Top 10 Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top